ArticleThe oncologist2023
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.BJU international · 2025Pooled it
- Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis.World journal of urology · 2026Trial
- Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate.JAMA network open · 2024Trial
- Article
- Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
- Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer.Prostate international · 2025Article
- Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer.JAMA network open · 2025Article
- Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada.Future oncology (London, England) · 2025Article
- Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Real-World Treatment Patterns and Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights From a Retrospective Cohort Study.Cancer management and research · 2025Article
- Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.Oncology reviews · 2025Review
- Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database.Urologic oncology · 2024Article
- Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Review
- Is There an Opportunity to De-Escalate Treatments in Selected Patients with Metastatic Hormone-Sensitive Prostate Cancer?Cancers · 2024Review
- Intensification of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: patient selection and overview of doublet and triplet therapy data.Advances in oncology · 2024Article
- The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice.The oncologist · 2023Article
- PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous androgen deprivation therapy ± first-generation non-steroidal antiandrogen was previously the standard-of-care for patients with metastatic castration-sensitive prostate cancer (mCSPC). Treatment intensification with novel hormonal therapy (NHT) or taxane chemotherapy is now approved and guideline-recommended for these patients.
methodsPhysician-reported data on adult patients with mCSPC from the Adelphi Prostate Cancer Disease Specific Programme were analyzed descriptively. We evaluated real-world treatment trends for patients with mCSPC in 5 European countries (United Kingdom, France, Germany, Spain, and Italy) and the United States (US), looking at differences between patients initiating treatment in 2016-2018 and in 2019-2020. We also investigated treatment trends by ethnicity and insurance status in the US.
resultsThis study found that most patients with mCSPC do not receive treatment intensification. However, greater use of treatment intensification with NHT and taxane chemotherapy was observed in 2019-2020 than in 2016-2018 across 5 European countries. In the US, greater use of treatment intensification with NHT in 2019-2020 than in 2016-2018 was observed for all ethnicity groups and those with Medicare and commercial insurance status.
conclusionsAs the number of patients with mCSPC who receive treatment intensification increases, more patients who progress to metastatic castration-resistant prostate cancer (mCRPC) will have been exposed to intensified treatments. Treatment options for patients with mCSPC and mCRPC overlap, suggesting that an unmet need will emerge for new therapies. Further studies are needed to understand optimal treatment sequencing in mCSPC and mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.